Delivery Order SPE2DB20D3104-SPE2DB23FV9C1
- Not listed
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The $1,238.51 firm fixed-price delivery order contract is for the supply of MESALAMINE DR 1.2 GM TABLET 120S, a pharmaceutical product. The contract has an ultimate completion date of May 28, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of MESALAMINE DR 1.2 GM TABLET 120S. The $1,951.60 firm fixed-price delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical division. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
- This federal contract award is for $3,192.04 to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical supplier to the U.S. government. The contract is a delivery order with a firm fixed price, awarded by the Defense Logistics Agency (DLA) to provide Mesalamine DR 1.2 GM Tablet 120S. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999.00 through December 31, 2025, which serves as the...
- This federal contract award, valued at $9,302.34, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4562954783 - MESALAMINE DR 1.2 GM TABLET 120S, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of December 1, 2023. It was awarded on November 30, 2023, and does not have a set-aside designation, indicating open...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,558,937,294 tablets of Mesalamine DR 1.2 GM. The $3,667.91 firm fixed-price delivery order has a completion date of November 1, 2022 and is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that provides a comprehensive range of...
- This federal contract award, valued at $4,322.17, is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp. The contract is for the supply of 4565936244 MESALAMINE DR 1.2 GM TABLET 120S, a pharmaceutical product. The contract has a firm fixed price and an ultimate completion date of September 26, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded this contract to provide these essential medical supplies to support military...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is a Delivery Order with a Firm Fixed Price valued at $4,513.59, for the supply of 4567781249 MESALAMINE DR 1.2 GM TABLET 120S. The award has an ultimate completion date of April 3, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,358.06 Firm Fixed Price delivery order contract is for the supply of Mesalamine DR 1.2 GM Tablets in quantities of 120. The contract has an ultimate completion date of March 14, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of MESALAMINE DR 400 MG CAPSULE 180S. The $1,560.29 firm fixed-price Delivery Order does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $7,894.88, is for the delivery of 4566251015 - MESALAMINE 800 MG DR TABLET 180S. The contract has an ultimate completion date of October 29, 2024, and is a Firm Fixed Price Delivery Order. The contract is not designated as a set-aside. In addition to this specific contract,...
- SPE2DB20D3104Indefinite Delivery Contract
- SPE2DB20D3104-SPE2DB23FV9C1Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The award, identified as SPE2DB20D3104 and SPE2DB23FV9C1, is a Firm Fixed Price Delivery Order contract valued at $9,490.48. The contract provides 4562312315 MESALAMINE DR 1.2 GM TABLET 120S, a pharmaceutical product, to support military treatment facilities and other federal healthcare programs. Amerisourcebergen, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to the DLA. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.5k | 9/26/23 |